Comments
FDA panel to weigh heart safety of Novo's new insulin
26.10.2012. | LONDON (Reuters) - A U.S. expert panel assessing Novo Nordisk's ultra long-acting insulin, degludec, will study its heart safety, raising a potential obstacle to approval in the world's top market....
